Sorafenib (Soranib Tablet) will be administered orally at a dose of 600mg daily without food for patients who have been treated with prior systemic therapy for advanced HCC. The study drug is continued until disease progression, unacceptable toxicity, withdrawal of consent, or study closure.~Response to sorafenib should be assessed at least every 8 weeks (± 7 days) by either CT scan or MRI.~After the treatment phase, subjects will undergo follow up for survival and the use of other anticancer treatments and/or therapies every 12 weeks (± 7 days) from the last dose and the survival follow up will be performed for at least 12 months after the enrollment of the last subject.
To investigate the efficacy and safety of sorafenib administered as later lines of treatment in patients with advanced HCC.